Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need
The Mount Sinai Health System in New York, NY, has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company. CastleVax is devoted to the commercial development of the Newcastle disease virus (NDV) vaccine platform technology originally developed in the laboratories …
Gromit Therapeutics Announces an Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai
Gromit Therapeutics, a clinical-stage biopharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases, and the Icahn School of Medicine at Mount Sinai in New York , NY (“Icahn Mount Sinai”) have announced today an exclusive license agreement to the …
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly progressing chronic kidney disease. Deployment of Renalytix’s …
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®
Real-world clinical utility in 1,112 patients tested with KidneyIntelX. KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its participation at the American Diabetes Association (ADA) 82nd Scientific Sessions® meeting in New Orleans from …
Mount Sinai Health System Launches i3 Prism, a Technology Commercialization Fund focused on Female and BIPOC Inventors
i3 Prism aims to bring new health care solutions to patients and society by advancing technologies from women and BIPOC inventors closer to the marketplace. Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, …
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
Sema4 (NASDAQ: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently published a study in Nature Communications using network modeling to identify novel …
Clinical Research Associates GRITT™ Resilience-based Methodology with Significantly Reduced Healthcare Utilization and Opioid Use in Patients with IBD
Research published in Clinical Gastroenterology and Hepatology following 394 IBD patients found significantly improved outcomes with use of GRITT™ methodology, augmenting previous findings Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, …
PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
Services Improve the Information Available to Oncologists and Pathologists in Determining Patient Risk Profiles and Treatment Diagnostic Industry Veteran Wayne Brinster Joins as CEO PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, …
Linus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). …
Linus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). …